title: CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia.
abstract: CD176 (Thomsen-Friedenreich antigen) is a tumor-associated carbohydrate structure. CD176 is expressed at the surface of human leukemic cells but is almost absent in normal and benign adult human tissues. Therefore, CD176 could be a promising target for antitumor immunotherapy. In the present study, pre-immunization with asialoglycophorin A (containing the CD176 oligosaccharide chains) was able to significantly improve the survival time of mice carrying CD176+ leukemia as compared to the control mice without the immunization. Furthermore, the passive transfer of CD176 antiserum which reacted only with the tumor-associated CD176 in cancer cells, was able to effectively prolong the survival time of CD176+ leukemia mice. In particular, the CD176 antiserum treatment could inhibit the growth and spreading of CD176+ leukemic cells in bone marrow, spleen, liver, and lung as evidenced by histopathological examination. CD176 antiserum could induce the apoptosis of CD176+ leukemic cells in vivo in a manner as previously observed in vitro. The data provided strong evidence that both CD176 antigen-based active immunotherapy and CD176 antibody-based passive immunotherapy lead to a therapeutic response in CD176+ leukemia mice. Therefore, both CD176 vaccine and CD176 antibody drug may be beneficial for the treatment of CD176+ leukemia patients.
authors.affiliation: Laboratory of Molecular and Experimental Pathology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, P.R. China.
authors.forename: Bin
authors.initials: B
authors.lastname: Yi
authors.forename: Zhe
authors.initials: Z
authors.lastname: Zhang
authors.forename: Min
authors.initials: M
authors.lastname: Zhang
authors.forename: Reinhard
authors.initials: R
authors.lastname: Schwartz-Albiez
authors.forename: Yi
authors.initials: Y
authors.lastname: Cao
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000276:immunology* / Q000378:metabolism; D017209:Apoptosis / Q000276:immunology; D001212:Asialoglycoproteins / Q000276:immunology; D001853:Bone Marrow / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage*; D007116:Immunization, Passive / Q000379:methods*; D016233:Immunotherapy, Active / Q000379:methods*; D007938:Leukemia / Q000628:therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C
chemical_list: D000906:Antibodies; D015295:Antigens, Tumor-Associated, Carbohydrate; D001212:Asialoglycoproteins; D019496:Cancer Vaccines; D007106:Immune Sera; C510444:asialoglycophorin AM; C016467:Thomsen-Friedenreich antigen